Guidance extended from year-end 2027 to early 2028, with operating expense reduction targets reiterated and achieved at a greater scale (now 35% year-over-year, 10% below guidance). Strategic focus ...
Recursion Pharmaceuticals Inc RXRX shares are under pressure Wednesday after new regulatory filings showed that Nvidia Corp NVDA has fully exited its investment in the AI‑focused drug‑discovery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results